IFW

PTO/SB/21 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995.	no persons are required to respond to a coll	ection of infor	mation unless it o	displays a valid OMB control number.			
	Application Number	10/601,13	27				
OTRANSMITTAL	Filing Date	June 19, 2003					
1 /	First Named Inventor	Carlos SCHULER					
FORM	Art Unit	3731					
(to be used for all correspondence after initial t	Examiner Name	UNASSI	GNED				
4	Attorney Docket Number	0047.10					
To a summer of Pages in This Submission		0047.10					
ENCLOSURES (Check all that apply)							
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD Remarks	ddress	Appeal of Appeal (Appeal (Appeal Status Other I below)	Enclosure(s) (please Identify			
SIGNA	TURE OF APPLICANT, ATTO	RNEY, OF	RAGENT				
Firm Name Nekdar Therapeutic	\$7		,				
Signature // // //	//						
Printed name Guy V. Tucker							
Date 74 0 CT 2006	F	Reg. No.	45,302				
CERTIFICATE OF TRANSMISSION/MAILING							
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:							
Signature Anna han							
Typed or printed name Anna Tran			Date	10/24/2006			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OCT 2 7 2006	IN THE UNITED STATES PAT		D TRAD	EMARK OFF	ICE
In the	e application of: Carlos SCHULER et al.) At	ty. Dock	et No.: 0047.1	10
TREMPENSON OF) Ex	aminer:	UNASSIGNE	ED
Applic	ation No.: 10/601,127) Gr	roup Art	Unit: 3731	
Filed:	06/19/2003)			
Title:	SYSTEMS AND METHODS FOR AEROSOLIZING PHARMACEUTICAL FORMULATIONS)))			

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, Virginia 22313-1450 on 10/24/2006

Signed: Ama 1

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The references listed in the attached Forms PTO/SB/08A may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

	\boxtimes	months of the date of	entry of ion; or b	ling date of a national application or an RCE; within three f the national stage as set forth in section 1.491 in an perfore the mailing date of a first Office action on the ars last).
	Attach	ed is Check No in the	he amou	unt of <u>\$0</u> .
	Please	charge the amount of	<u>\$</u> to	Deposit Account 500348
\boxtimes		determined that any ac such fees to Deposit A		I fees are due, the Commissioner is hereby authorized to 500348.
				Respectfully submitted,
				NEKTAR THERAPEUTICS
Dated:	2400	1200S	Ву:	Guy V. Tucker Reg. No. 45,302

NEKTAR THERAPEUTICS 150 Industrial Road San Carlos, CA 94070 (650) 620-5501

Form PTO/SB/08A (Modified)

Information Disclosure Statement By Applicant

Carlos SCI	Application No.:
0047.10	10/601,127
Applicant:	
Carlos	SCHULER et al.
Filing Date:	Group:
06/10/2003	3731

U.S. Patent Documents

Examiner						Sub-	Filing
Initial	No.	Patent No.	Date	Patentee	Class	Class	Date
		5,161,524	11/10/92	Evans, Rix E.			
,							
			· · · · · · · · · · · · · · · · · · ·				

						-	
		<u> </u>					
				-			
,							

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.